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Abstract
Microparticles (MPs), membrane fragments of 0.1–1.0 μm, are derived from many cell types in 
response to systemic inflammation. Acute liver failure (ALF) is a prototypical syndrome of 
systemic inflammatory response syndrome (SIRS) associated with a procoagulant state. We 
hypothesized that patients with ALF develop increased procoagulant MPs in proportion to the 
severity of systemic complications and adverse outcome. Fifty patients with acute liver injury 
(ALI), 78% of whom also had hepatic encephalopathy (HE; ALF), were followed until day 21 
after admission. MPs were characterized by Invitrox Sizing, Antigen Detection and Enumeration, 
a light-scattering technology that can enumerate MPs as small as 0.15 μm, and by flow cytometry. 
Procoagulant activity was assessed by a functional MP-tissue factor (MP-TF) assay. Sixteen 
patients (32%) died and 27 (54%) recovered without liver transplantation (LT). Total MPs (0.15–
1.0 μm) were present in nearly 19-fold higher concentrations in ALI/ALF patients, compared to 
healthy controls (P < 0.0001). MP-TF assays revealed high procoagulant activity (9.05 ± 8.82 
versus 0.24 ± 0.14 pg/mL in controls; P = 0.0008). MP concentrations (0.28–0.64 μm) were higher 
in patients with the SIRS and high-grade HE, and MPs in the 0.36–0.64-μm size range increased in 
direct proportion to SIRS severity (P < 0.001) and grade of HE (P < 0.002). Day 1 MPs (0.28–0.64 
μm) correlated with laboratory predictors of death/LT (higher phosphate and creatinine; lower 
bicarbonate), and day 1 and 3 MPs were higher in patients who died or underwent LT, compared to 
spontaneous survivors (P ≤ 0.01). By flow cytometry, 87% of patients had circulating CD41+ MPs, 
indicating platelet origin. Conclusion: Highly procoagulant MPs of specific size ranges are 
associated with the SIRS, systemic complications, and adverse outcome of ALI/ALF. MPs may 
contribute to the multiorgan system failure and high mortality of ALF.
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Acute liver failure (ALF), the clinical syndrome subsequent to acute liver injury (ALI), is 
characterized by coagulopathy, hepatic encephalopathy (HE), and, frequently, death without 
liver transplantation (LT).1 An intense systemic inflammatory response syndrome (SIRS),2 
often in the absence of infection, predicts multiorgan system failure (MOSF) and death.3 
Although proinflammatory cytokines originating from the necrotic liver may trigger the 
systemic complications of ALF, mediators of the syndrome are incompletely defined, and 
others with effects on vascular endothelium and hemostasis likely coexist.4
Although abnormalities in hemostasis are an invariable feature of ALF syndrome, patients 
rarely develop bleeding complications despite dramatically elevated international normalized 
ratio of prothrombin time (INR).5 Indeed, patients with ALF appear more prone to 
thrombotic, rather than bleeding, complications,6 and intrahepatic thrombosis may 
exacerbate the initial injury.7 Recently, we6,8 and others9 have suggested that patients with 
ALF generally maintain normal or hypercoagulable global hemostasis, as determined by 
thromboelastography (TEG) and thrombin generation assays. Moreover, maximal clot 
strength by TEG increases in proportion to the number of SIRS components, possibly 
resulting from increased release of factor VIII and von Willebrand factor from activated/
injured endothelial cells (ECs),10 providing a plausible explanation for the absence of 
bleeding, even in the most critically ill subjects with the highest INR.
In the presence of a relatively prothrombotic state, patients with ALF also frequently 
develop thrombocytopenia. 11 In other acute illnesses characterized by a prominent SIRS, 
such as sepsis, thrombocytopenia portends an ominous prognosis,12–14 particularly in 
patients with declining platelet counts after admission. 15 Although platelet fragmentation is 
well recognized in sepsis as part of disseminated intravascular coagulation (DIC), platelet 
fragmentation has not been studied in patients with ALF, who often have a DIClike 
phenotype, except for factor VIII levels, which tend to be low in DIC, but very high in 
ALF.10,16
Microparticles (MPs) are membrane fragments (ranging in size from 0.1–1.0 μm) derived 
from many cell types.17 Activation of cells or platelets by systemic inflammation initiates an 
enzymatically catalyzed reaction whereby chards of plasma membrane bleb inside out into 
the circulation, exposing procoagulant phosphatidylserine and cellular epitopes conferring 
functionality. MPs are particularly prothrombotic when they display tissue factor (TF), a 
transmembrane protein.18,19 Increasing experimental evidence suggests that MPs play a 
functional role in regulating vascular tone in patients with cirrhosis20 and sepsis,21 
conditions that bear many similarities to ALF syndrome.22 Recent advances in light-
scattering technology have permitted the enumeration and sizing of very small MPs of 0.15–
0.5 μm, below the limit of detectability by standard flow cytometry, allowing an exploration 
of the role of MPs in disease pathogenesis.23
We hypothesized that patients with ALI/ALF may develop increased procoagulant MPs in 
plasma as a function of the severity of the SIRS. Furthermore, we sought to explore a 
potential pathogenic role of MPs in the systemic complications and outcome of patients with 
ALI/ALF.
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This work was approved by the Ancillary Studies Committee of the Acute Liver Failure 
Study Group (ALFSG), and patients or their nearest of kin provided informed consent under 
the ALFSG Registry modified for the collection of platelet-poor plasma (PPP) by the 
institutional review board of Virginia Commonwealth University (VCU; Richmond, VA). 
Fifty consecutive patients with ALI/ALF were recruited prospectively from admissions at 
VCU Medical Center. ALI was defined as liver injury in a patient with no known previous 
liver disease, an admission INR of ≥1.5, and a duration of illness of ≤26 weeks. ALF was 
defined as ALI in the presence of HE. Some patients in the current study population also 
participated in two previous studies exploring hemostasis in ALI/ALF.6,8 For the present 
study, 13 healthy volunteer controls were also recruited for the collection of 5 mL of whole 
blood for plasma. Controls were of similar age (39 years) and gender distribution (54% 
female) as the study population (P = 0.6 and 0.2, respectively).
SIRS components were determined at time of admission to the study by standard criteria, 
and the presence of the SIRS was defined as two to four positive SIRS components.24
Complications of ALI/ALF, including bleeding, thrombosis, and infection, were defined 
previously6 and occurred late after admission (on or after day 3). Bleeding sites included 
gastric mucosal erosions (N = 6) and cutaneous (N = 3), none of which lead to the need for 
blood transfusion. Thrombotic events included occlusion of renal replacement therapy 
(RRT) catheters (N = 6), portal venous thrombosis (N = 2), and limb vessel thrombosis (N = 
1). Sites of infection included lung (N = 5), urine (N = 4), blood (N = 3), and ascites (N = 1) 
and were identified relatively late after admission (>3 days after admission). As per ALFSG 
protocol, outcomes (death, LT, or transplantfree survival [TFS]) were determined at day 21 
after admission.
Laboratory Methods
Standard laboratories were collected on admission to the hospital (day 1) and daily for 7 
days. For the analyses herein, laboratories drawn on days 1 and 3 after admission were 
analyzed. Whole blood from days 1 and 3 was also collected for PPP in 5-mL citrated 
Vacutainer tubes. Because enrolled patients were purposely chosen to represent a wide range 
of liver injury severity, blood was drawn by in-dwelling venous catheters, radial artery 
catheters, and butterfly needle catheters, depending upon whether patients were in a floor 
bed or intensive care unit, and the availability of vascular access. Blood was centrifuged at 
1,500×g for 20 minutes at room temperature, aliquotted, and PPP was frozen at −80°C 
within 2 hours of drawing.
MP Sizing and Enumeration—MPs were analyzed by Invitrox Sizing, Antigen 
Detection, and Enumeration (ISADE; Invitrox, Inc., Research Triangle Park, NC).23 Batches 
of 10–20 PPP samples, randomly selected, were injected into the detection chamber using a 
fixed volume of 200 μL/sample. Testing time for sizing and enumeration was 6 minutes/
sample. To eliminate any contribution from buffer/diluent, background counts were 
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subtracted from each sample result. The concentration of MPs was recorded as log10 MP/mL 
for the following size distributions: 0.15–0.27, 0.28–0.35, 0.36–0.64, and >0.64 μm. The 
ability of ISADE to resolve a mixture of standard control polystyrene beads with known 
sizes (0.2, 0.24, 0.3, 0.35, 0.4, and 0.5 μm) is shown in Fig. 1A. Both the size and number of 
beads were accurately reported with a small scatter of size around each peak, which resulted 
from a small variation in bead size, confirmed by scanning electron microscopy (SEM).
MP tissue factor (MP-TF) activity assay. MPs were isolated from 250 uL of PPP by 
centrifugation (20,000×g for 30 minutes at 4°C). The MP pellet was resuspended by 
sonication in 250 uL of HEPES-buffered saline containing 0.5% bovine serum albumin 
(BSA) (20 mM of HEPES, 120 mM of NaCl, and 1 mg/mL of BSA). A previously 
described25 two-stage chromogenic assay was employed with the following modifications. 
First, MPs were incubated for 2 hours with 2.5 mM of CaCl2, 1 nM of factor VIIa, and 150 
nM of factor X (FX) in the presence and absence of a TF blocking antibody (Ab). Next, 
absorbance measurements (to measure generated FXa) were made for every 30 seconds for 
30 minutes after the addition of ethylenediaminetetraacetic acid and FXa chromogenic 
substrate (Pefachrome 8595; Centerchem, Inc., Norwalk, CT). TF activity was calculated in 
relation to an Innovin TF standard.
Flow cytometry was performed on a Becton Dickinson BD LSRII (Becton Dickinson, 
Franklin Lakes, NJ) as per International Society on Thrombosis and Hemostasis 
standardization.26 Briefly, PPP (10 μL) at 37°C was stained with Ab for 15 minutes. 
Secondary Ab was added for an additional 10 minutes. Samples were then diluted with 0.9 
mL of Annexin V binding buffer (BD) with or without calcium. An equal volume of 
Beckman Coulter Flow-Count beads (Beckman Coulter, Inc., Brea, CA) were added to the 
samples. Ten thousand sample events were collected within the MP gate, and results were 
compared to isotope controls.
Statistical Analyses
MP concentrations in each size distribution were log10-transformed for analysis. Continuous 
variables were analyzed for normality of distribution and expressed as mean ± standard 
deviation (SD) or median (range) and analyzed by analysis of variance or Wilcoxon’s/
Kruskal-Wallis’ rank-sums test, as appropriate. Categorical variables were analyzed by chi-
square test and correlation of continuous data by Pearson’s correlation (r value). Both uni- 
and multivariate logistic regression was used to model TFS using demographic and MP data. 
For stepwise logistic regression modeling, a P = 0.25 significance level was required for 
entry into the model, whereas a P = 0.05 significance was required for a covariate to remain 
in the model. Data were analyzed using JMP 8.0, and multivariate analyses were performed 
with SAS (SAS Institute Inc., Cary, NC). Significance was defined as a P value ≤0.05.
Results
Relationship of Baseline Patient Characteristics to Outcome
Demographic, clinical, and laboratory parameters of the study population are depicted in 
Table 1 according to outcome, either spontaneous recovery (TFS) or LT/death. Mean age of 
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the entire population was 43 years, approximately two thirds were women, and half had 
acetaminophen (APAP) hepatotoxicity. Etiologies of liver injury in the non-APAP group 
included hepatitis B (in 7), idiosyncratic drug reactions (in 6), autoimmune hepatitis (in 5), 
indeterminate (in 3), and ischemia/herpes simplex virus/heat shock/Amanita mushroom 
poisoning (in 1 each). Hepatic encephalopathy (ALF) was present in 39 patients (78%) on 
admission, 24 of whom (62%) developed high-grade (grade 3/4) encephalopathy within the 
first 7 days of admission. The SIRS was present on admission in 28 patients (56%). In 
univariate analysis, predictors of death/LT included older age (P = 0.017), non-APAP 
etiology (P = 0.010), development of high-grade HE (P = 0.005), presence of SIRS on 
admission (P = 0.019), higher admission lactate (P < 0.0001), phosphate (P = 0.037), total 
bilirubin (P = 0.016), activated partial thromboplastin time (aPTT; P = 0.010), and factor 
VIII (P = 0.013), and lower alanine aminotransferase (ALT; P = 0.0003), bicarbonate (P = 
0.019), and fibrinogen (P = 0.007).
Enumeration, Sizing, and Procoagulant Activity of Microparticles in Plasma of Patients 
With ALI/ALF, Compared to Healthy Controls
Three dominant MP size ranges were detected in plasma from ALF patients and healthy 
controls (0.15–0.27, 0.28–0.64, and >0.64 μm; Fig. 1B). Of total MPs in the range of 0.15–
1.0 μm, a mean of 99.5% were <0.5 μm, the size limit of detection of standard flow 
cytometry (data not shown). Mean total MPs (0.15–1.0 μm) in patients with ALI/ALF were 
present in nearly 19-fold greater number than healthy controls of similar mean age and 
gender distribution (Fig. 2A; P < 0.0001). MPs of all size ranges were present in 
significantly greater concentrations in patients with ALI/ALF than in healthy controls (data 
not shown). TF-dependent procoagulant activity of MPs was determined using an in-house 
MPTF assay. Mean MP-TF activity was 38-fold higher in PPP from 34 ALI/ALF patients, 
compared to 13 healthy control patients (9.05 ± 8.82 versus 0.24 ± 0.14 pg/mL, respectively; 
Fig. 2B; P = 0.0008).
Relationship of MP Number and Size to Admission Laboratories and Late Complications of 
ALF
Table 2 depicts the relationship of log10 MP number/mL according to size with 
complications and laboratories on admission for ALI/ALF. Concentrations of large MPs 
(>0.64 μm) were present in significantly greater number in plasma from patients with non-
APAP, compared to those with APAP hepatotoxicity, but were otherwise similar in patients 
with and without the SIRS on admission and those who developed specific complications of 
ALF. Significant differences were also not observed in concentrations of the smallest MPs 
(0.15–0.27 μm) according to etiology of liver injury, the presence of the SIRS, or specific 
complications of ALF. In contrast, concentrations of MPs of intermediate size (0.28–0.64 
μm) were higher in patients with the presence of the SIRS on admission (9.19 ± 0.91 with 2–
4 SIRS versus 8.71 ± 0.51/mL with 0–1 SIRS; P = 0.033), and those in the 0.36–0.64-μm 
size range were particularly closely related to the number of SIRS on admission (Fig. 3A; P 
= 0.0002). Similarly, MPs of intermediate size (0.28–0.64 μm) were present in higher 
concentration in patients with high-grade HE (grade 3–4) than those with grade 0–2 
encephalopathy (9.24 ± 0.95μm versus 8.74 ± 0.52/mL, respectively; P = 0.026), and those 
in the 0.36–0.64-μm size range were again particularly closely related to the individual grade 
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of encephalopathy (Fig. 3B; P < 0.002). MPs of intermediate size range were also present in 
higher concentration in patients who developed late (after day 3) complications of minor 
bleeding (none requiring blood transfusion) and renal failure requiring RRT. MP 
concentrations of any size range were not significantly different in patients who developed 
infectious or thrombotic complications, compared to those who did not (Table 2A).
Concentrations of MPs of intermediate size range (0.28–0.64 μm), and particularly those in 
the 0.36–0.64-μm range, were also the most strongly related to laboratories associated with 
the SIRS and poor outcome after ALF (Table 2B). Specifically, higher MP concentrations 
were associated with higher phosphate (r = 0.52; P < 0.0001), creatinine (r = 0.31; P = 
0.030), and factor VIII (r = 0.38; P = 0.029) as well as lower bicarbonate (r = −0.44; P = 
0.002) and ALT (r = −0.37; P = 0.009). MP concentrations in the 0.28–0.64-μm size range 
also directly correlated with MP-TF activity in the 34 patients in whom these assays were 
performed (r = 0.43; P = 0.012).
Relationship of MP Concentration and Size to Outcome of ALI/ALF
MPs of intermediate size (0.28–0.64 μm) were significantly related to the outcome of 
ALI/ALF at day 21 (Fig. 4), whereas MPs of smallest (0.15–0.27 μm) and largest (>0.64 
μm) size ranges were not (data not shown). MP log10 concentrations of MPs of 0.28–0.64 
μm on day 1 were greater in patients who died or were transplanted by day 21 than in 
transplantfree survivors (9.31 ± 0.94 versus 8.71 ± 0.51/mL; P = 0.006; Fig. 4A). Similarly, 
MP concentrations in plasma from day 1 were higher in patients who died, compared to 
those who survived overall (Fig. 4B; P = 0.010). MP concentrations in plasma from day 1 
correlated modestly with concentrations in samples from day 3 (r = 0.39; P = 0.012), which 
were available in 43 patients; 3 patients died between days 1 and 3. MP concentrations in the 
intermediate size range increased from days 1 to 3 in 20 patients and decreased in 23 
patients, but the changes between days 1 and 3 were not significantly related to outcome 
(data not shown). However, MP concentrations in plasma from day 3 were also higher in 
those who died or underwent LT by day 21 than in transplant-free survivors (Fig. 4C; P = 
0.0002) and in patients who died, compared to those who survived overall (Fig. 4D; P < 
0.05). Concentrations of MPs greater than ~log108.5 in day 3 plasma identified all but 1 
patient who died or underwent LT (Figs. 4C,D).
Because certain static patient characteristics were found in univariate analyses to affect 
outcome and MP concentrations (Tables 1 and 2), we performed stepwise multivariate 
logistic regression analysis using predictors with P < 0.25 (age, gender, and etiology) to 
determine whether MP concentrations were independently associated with death/LT. Only 
MP concentration (0.28–0.35, 0.36–0.64, or 0.28–0.64 μm) was found to be independently 
associated with outcome in the final multivariate models across the three size ranges (Table 
3). In the first model, each 10-fold increase in the number of MPs of 0.28–0.35 μm size 
increased the likelihood of death/LT by 4.9-fold (P = 0.042), whereas APAP etiology 
decreased the likelihood of death/LT by approximately 75% (P = 0.038). In the second 
model, each 10-fold increase in MP of 0.36–0.64 μm size increased the likelihood of 
death/LT by 11-fold (P = 0.003), whereas APAP was not an independent predictor of 
outcome. In the third model, each 10-fold increase in MP of 0.28–0.64 μm size increased the 
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likelihood of death/LT by 6.8-fold (P = 0.027), whereas APAP etiology was also not an 
independent predictor of outcome.
Phenotyping of MPs
Using Abs against specific cell membrane markers, we performed flow cytometry on PPP 
from a subset of 31 patients with ALI/ALF. Markers were chosen according to sites of injury 
in ALF and known sources of MPs in circulation in patients with prominent SIRS (platelets, 
hepatocytes, monocytes, and ECs). CD41, a marker of platelet membranes, was detected in 
PPP from 27 of 31 (87%) patients (Fig. 5). Asialoglycoprotein receptor (ASGPR), a specific 
marker of hepatocyte plasma membranes, was present in the MP fraction of 7 (23%) 
patients. In contrast, CD18+ MPs derived from monocytes and CD144+ MPs derived from 
ECs were detected in a small minority of plasma samples (3 and 1 patients, respectively). 
Although there were no significant associations between phenotypes and severity of ALI/
ALF, the numbers of patients in these subgroups was too small to analyze. Thus, flow 
cytometry determined that platelets are the predominant source of circulating MPs in 
patients with ALI/ALF.
Discussion
The data presented suggest that plasma MP concentrations of a specific size range are 
associated with the systemic complications and adverse outcome of patients with ALI/ALF, 
and that MPs thereby represent an important link between systemic inflammation and 
activation of hemostasis in this syndrome. Specifically, higher concentrations of MPs (0.28–
0.64 μm) were observed in patients with the SIRS, high-grade HE, and in those who 
developed renal failure and/or minor bleeding complications, and correlated with laboratory 
predictors of poor outcome (phosphate, bicarbonate, and creatinine). Furthermore, plasma 
MP concentrations were significantly higher in patients who died or underwent LT than in 
spontaneous survivors and higher in patients who died, compared to those who survived; 
multivariate logistic regression analysis identified MPs in the 0.28–0.64-μm range as 
independently associated with death/LT, particularly in the 0.36–0.64-μm range. Although 
MPs of multiple phenotypes were present, the majority of patients had detectable MPs of 
platelet origin, and MP-TF assays demonstrated that circulating MPs in these patients were 
markedly procoagulant.
In most previous publications, the detection and characterization of MPs has been impaired 
by limitations in technology that relied on flow cytometry.23 Specifically, flow cytometry 
cannot reliably size and enumerate MPs <0.5 μm, an important point of emphasis 
considering our finding that >99% of circulating MPs in patients with ALF were <0.5 μm. 
ISADE, a novel light-scattering technology, determines particle size directly from the 
intensity of light scattered at a defined angle, assessing single particles one at a time, and 
resolving MPs accurately to a size of 0.15 μm. The current work demonstrates the power of 
this technology over standard flow cytometry because it allowed the accurate enumeration of 
MPs in the 0.28–0.64-μm range, where the most important differences were observed in our 
study population. A recent investigation of hemostasis in 20 patients with ALF found a 4-
fold increase in TF-independent procoagulant activity in the MP fraction of PPP, compared 
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to healthy controls,9 supporting our findings using ISADE and flow cytometry. However, 
such functional assays do not provide information about MP size distribution or cell of 
origin.17
The ability of ISADE to enumerate MPs by size may represent a distinct advantage of this 
technology, because size profoundly affects MP physical properties and functionality and 
therefore likely determines specificity. For example, MPs of specific size differ in surface 
area and angles of curvature, which, in turn, influences the surface chemistry and stability of 
the MP. Smaller MPs carry smaller numbers of epitopes and are more adherent to cell 
surfaces because the entropy term for the interaction is smaller. They also display greater 
distortion of epitopes bound to their surface because of their greater angle of curvature. In 
contrast, larger MPs require higher amounts of energy to stabilize interaction between a 
target cell and the MP. Particle size also affects its distribution within the microcirculation. 
Therefore, the findings in the present work that MPs of 0.28–0.64 μm correlate with many 
aspects of ALF syndrome, and that the 0.36–0.64-μm size range correlates particularly 
strongly, may be highly relevant.
Increasing experimental evidence suggests that MPs are effectors of inflammation and 
coregulators of hemostasis and/or thrombosis in acute and chronic diseases.27–30 In patients 
with sepsis, MPs play an important role as messengers from inflammatory cells to ECs, 
myocardial cells, and smooth muscle cells, leading to microcirculatory thrombosis, 
peripheral tissue ischemia, and circulatory collapse.21 These features of septic shock also 
characterize patients with ALF with MOSF.2 Platelet MPs, in particular, are candidate 
effectors of sepsis and ALF syndromes, because patients with both conditions may develop 
microvascular thrombosis leading to peripheral tissue hypoxia. 31,32 The data reported herein 
support a pathogenic role for MPs in the 0.28–0.64-μm size range in mediating ALF 
syndrome. The direct correlation between MP number and factor VIII levels also suggests 
that MPs may play a role in vascular endothelial cell activation/injury of ALF, the severity of 
which directly correlates with mortality. 10,33 Whether MPs serve as mediators of the 
systemic complications of ALF or are simply biomarkers of inflammation cannot be 
determined conclusively from our data; however, it appears likely that they represent both 
the cause and the effect of systemic inflammation.
Recent studies have also incriminated MPs in the pathogenesis of chronic liver diseases 
(CLDs).30 Patients with cirrhosis have increased circulating MPs derived from leukocytes, 
ECs, and hepatocytes, compared to healthy controls, and concentrations of MPs increase 
with increasing severity of cirrhosis.20 MPs isolated from PPP of subjects with cirrhosis 
were shown in vitro and in experimental animals to impair vasoconstrictor response and may 
thereby cause the vasoplegia of end-stage liver disease. Similarly, T-lymphocyte-derived 
CD4+ and CD8+ MP numbers were higher in patients with nonalcoholic fatty liver disease 
and chronic hepatitis C than healthy controls and correlated with disease activity.34,35 In 
contrast to the present work, the number of CD41+ (platelet-derived) MPs in these 
populations with CLD were not significantly higher than healthy controls nor were they 
proportional to the severity of disease. However, both of these studies were performed using 
flow cytometry and may have thereby missed a possible effect of platelet-derived MPs, most 
of which (as shown herein) are below the limit of detection by flow cytometry. These studies 
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and the present work suggest that increased production of platelet MPs may be restricted to 
acute conditions characterized by a prominent SIRS.
In addition to systemic effects of MPs implied by the association of MP concentrations and 
systemic complications of ALF, procoagulant MPs may also serve to exacerbate the primary 
liver injury. In a mouse model of APAP hepatotoxicity, activation of coagulation within the 
necrotic liver increases the primary APAP-induced injury and is greatly ameliorated by 
heparin administration.7 Furthermore, the prothrombotic effect of APAP is also greatly 
ameliorated in mice expressing low levels of TF, providing indirect evidence that liver-
derived TF may mediate the activation of coagulation.7 Other experimental models also 
support a role for secondary activation of coagulation within the acutely injured liver in the 
pathogenesis of liver failure.36,37 Because thrombin generation requires exposure of anionic 
phospholipids on cellular and/or MP surfaces, intrahepatic MPs would be reasonable 
candidate platforms on which coagulation occurs.
MP-TF assays have also shown that the population of circulating MPs is highly procoagulant 
in a TF-dependent manner. Although this study did not determine the cellular origin of the 
TF-expressing MPs, the measured levels are among the highest we have ever observed in a 
variety of prothrombotic conditions, including cancer,38 sickle cell disease,39 and human 
immunodeficiency virus (Baker and Key, unpublished data). Furthermore, these levels 
exceed, by 3- to 4-fold, the transient peak level of monocyte-derived MPTF activity in 
plasma that we have measured in healthy volunteers receiving endotoxin.40 Although these 
intriguing observations might be explained by the release of TF from the necrotic liver into 
the circulation, proof of this hypothesis awaits confirmation.
There are important limitations to the current study. First, we recognize that the use of flow 
cytometry to phenotype MPs could not determine the cellular origin of most of the MPs in 
the 0.28–0.64-μm size range because of the above-noted poor sensitivity of this technology 
to detect MPs <0.5 μm. Unfortunately, the current state of technology for phenotyping MPs 
is limited to flow cytometry, which indicated that platelets are the major species of larger 
MPs in the circulation. We assume that the smaller MPs of 0.28–0.50 μm are part of a size 
continuum, but proof requires the development of new methods. Second, the manner in 
which blood was drawn for PPP could not be standardized, because the study population 
represented a wide range of acuity of illness. Therefore, less acutely ill patients were more 
likely to have had blood sampled from a butterfly catheter during a brief use of a venous 
tourniquet, and those more acutely ill were more likely to have had blood samples from 
indwelling central venous or radial artery catheters without the use of a tourniquet. We 
speculate that MP number would be increased by the former mode of blood collection. 
However, MP number was higher in the latter population, which would argue that the 
manner of collection did not bias our results.
In conclusion, the data presented suggest that MPs of 0.28–0.64 μm are independent 
predictors of systemic complications and poor outcome in patients with ALI/ALF and 
support a pathogenic role of MPs in ALF syndrome, rather than simply representing markers 
of disease acuity. The marked elevation of MP-TF activity provides an additional mechanism 
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by which patients with ALI/ALF maintain normal or hypercoagulable global hemostasis and 
rarely experience significant bleeding complications.
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Ab antibody
ALF acute liver failure
ALFSG the Ancillary Studies Committee of the Acute Liver Failure Study Group
ALI acute liver injury
ALT alanine aminotransferase
APAP acetaminophen (paracetamol)
aPTT activated partial thromboplastin time
ASGPR asialoglycoprotein receptor
BSA bovine serum albumin
CLD chronic liver disease





INR international normalized ratio of prothrombin time
ISADE Invitrox Sizing, Antigen Detection and Enumeration
LT liver transplantation
MOSF multiorgan system failure
MPs microparticles
MP-TF microparticle tissue factor assay/activity
PPP platelet-poor plasma
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MP charcterization by ISADE. (A) Demonstration of the ability of ISADE to resolve a 
mixture of polystyrene beads with sizes of 0.2, 0.24, 0.3, 0.35, 0.4, and 0.5 μm. Both the size 
and number of beads were accurately reported. The low counts noted on either side of each 
bead size results from a small variation in bead size, confirmed by SEM. (B) Enumeration 
and sizing of MPs in PPP from a patient with ALF from disulfuram. Tracings from two 
different freeze-thawed aliquots are shown, demonstrating the small intersample variability 
of the results. Three distinct size ranges were identified, separated by solid black lines. Mid-
sized MPs of 0.28–0.64 μm were most closely associated with ALF complications, 
laboratories, and outcome.
Stravitz et al. Page 14














MP concentration and procoagulant activity in patients with ALI/ALF and normal healthy 
controls. (A) Total log10MP/mL of size range 0.15–1.0 μm in 50 ALI/ALF patients on 
admission to the hospital and 13 healthy controls of similar age and gender distribution (P < 
0.0001). (B). MP-TF activity in 34 ALI/ALF patients on admission to the hospital and 13 
healthy controls (P = 0.0008). Error bars indicate mean ± SD.
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Relationship of MP concentration to number of positive SIRS components on admission for 
ALI/ALF and grade of HE. (A) Log10MP/mL (0.36–0.64 μm) versus number of positive 
SIRS components on admission (P = 0.0002). (B) Log10 MP/mL (0.36–0.64 μm) versus 
maximal grade of HE during the first 7 days of admission (P = 0.0015). Error bars indicate 
mean ± SD.
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Relationship of MP concentration (0.28–0.64 μm) to outcome of ALI/ALF. (A) 
Log10MP/mL on day 1 of admission according to outcome by day 21, TFS, or death/LT (P = 
0.006). (B) Log10MP/mL on day 1 according to overall survival by day 21 (P = 0.010). (C) 
Log10MP/mL on day 3 of admission according to TFS versus death/LT by day 21 (P = 
0.0002). (D) Log10MP/mL on day 3 according to overall survival by day 21 (P < 0.05). The 
range of MP concentration on day 3 was lower than the range on day 1 samples as a result of 
early mortality of 3 patients with high day 1 MP concentrations. Error bars indicate mean ± 
SD.
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Prevalence of MP phenotypes in plasma of patients with ALI/ALF by flow cytometry.
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Table 1
Demographic and Clinical Characteristics of Study Population on Admission to the Hospital for ALI/ALF
Clinical Feature
Total Study Population Transplant-Free Survivors Death/LT
P*(N = 50) (N = 27) (N = 23)
Demographic and clinical characteristics
 Age, years 43.1 ± 13.5 38.9 ± 13.2 48.0 ± 12.5 0.017
 Female gender, % 64 67 61 0.670
 BMI, kg/m2 28.2 ± 6.8 27.4 ± 5.0 29.1 ± 8.4 0.381
 Etiology of ALF, % 0.010
  APAP 50 67 33
  Non-APAP 50 33 70
 HE grade, % grade 3–4 48 30 70 0.005
 SIRS N, % 2–4 56 41 74 0.019
Laboratories
 Ammonia, μM (venous) 80.3 ± 45.2 72.5 ± 39.3 88.8 ± 50.5 0.227
 Lactate, mg/dL 5.9 ± 5.6 3.1 ± 3.4 9.8 ± 5.7 <0.0001
 Phosphate, mg/dL 3.3 ± 2.2 2.7 ± 1.3 4.0 ± 2.8 0.037
 pH (arterial) 7.35 ± 0.13 7.38 ± 0.13 7.33 ± 0.14 0.230
 Bicarbonate, mg/dL 19.7 ± 7.7 22.0 ± 5.8 17.0 ± 8.8 0.019
 Creatinine, mg/dL 1.0 (0.4–7.5) 0.9 (0.4–7.5) 1.3 (0.4–5.2) 0.340
 Total bilirubin, mg/dL 5.0 (0.3–44.2) 4.4 (0.9–29.4) 13.3 (0.3–44.2) 0.016
 INR 3.4 ± 1.8 3.1 ± 1.3 3.8 ± 2.1 0.175
 aPTT, seconds 47.4 ± 14.7 42.4 ± 9.8 53.0 ± 17.3 0.010
 ALT, IU/L 3,579 ± 2,765 4,813 ± 2,840 2,129 ± 1,852 0.0003
 Fibrinogen, mg/dL 183 ± 71 211 ± 63 142 ± 63 0.007
 Factor VIII, % normal 435 ± 206 364 ± 143 537 ± 243 0.013
*
P refers to comparison of transplant-free survivors and those who died or underwent LT.
Abbreviation: BMI, body mass index.
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Table 3
Step-Wise Multivariate Logistical Regression Analyses of Death/LT Using Demographic and Clinical 
Variables and Microparticle Number According to Size
Model Variables P OR 95% CI
1 Etiology APAP 0.038 0.253 0.069–0.928
MP 0.28–0.35 μm day 1 0.042 4.932 1.060–22.943
2 Etiology APAP 0.078 0.272 0.064–1.159
MP 0.36–0.64 μm day 1 0.003 11.093 2.270–54.223
3 Etiology APAP 0.056 0.280 0.070–1.031
MP 0.28–0.64 μm day 1 0.027 6.776 1.245–36.889
Step-wise logistic regression was performed on variables with a P = 0.25 entry criterion in univariate analysis and P = 0.05 criterion to remain in 
the model. Odds ratios for continuous variables are per unit change.
Abbreviations: OR, odds ratio; 95% CI, 95% confidence interval.
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